# A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

> **NCT02115815** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 246 (actual)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** RSV sF 20 mcg
- **BIOLOGICAL:** MEDI7510 (20 mcg RSV sF)
- **BIOLOGICAL:** RSV sF 50 mcg
- **BIOLOGICAL:** MEDI7510 (50 mcg RSV sF)
- **BIOLOGICAL:** RSV sF 80 mcg
- **BIOLOGICAL:** MEDI7510 (80 mcg RSV sF)

## Key facts

- **NCT ID:** NCT02115815
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2016-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02115815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02115815, "A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02115815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*